HERCULES, CA --(Marketwired - December 16, 2015) - Bio-Rad Laboratories, Inc. (
The D-100 is a fully automated instrument utilizing high-performance liquid chromatography (HPLC) technology. It is designed to meet the needs of medium and high volume clinical laboratories, for greater throughput, high quality results, and simplified workflow for A1c testing. The system delivers rapid results without sacrificing the ability to detect hemoglobin variants, which can interfere with the interpretation of test results. Earlier this year, Bio-Rad obtained CE marking and released the D-100 System in Europe, Canada, and several countries in Asia-Pacific.
"Bio-Rad is pleased to continue its tradition of helping to manage the global epidemic of diabetes," said John Hertia, Bio-Rad President, Clinical Diagnostics Group. "Bio-Rad pioneered HbA1c testing over 30 years ago, and our newest platform leverages our expertise in this area to meet our customers' evolving needs."
The International Diabetes Federation estimates over 415 million adults worldwide are living with diabetes and this number is expected to increase to 642 million by 2040. Early detection and treatment of diabetes can decrease the risk of developing long term complications resulting from this disease.
About Bio-Rad
Bio-Rad Laboratories, Inc. (
Press Contact: Bio-Rad Laboratories, Inc. Tina Cuccia, Corporate Communications 510-724-7000 Email contact